Vir Biotechnology, Inc. (VIR) Stock Analysis & Investment Frameworks
Vir Biotechnology, Inc. (VIR) stock analysis on Invetso. Review Vir Biotechnology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Vir Biotechnology, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Vir Biotechnology, Inc. Key Financial Metrics
- Market Cap: $1.79B
- Revenue: $68.56M
- ROE: -29.99%
- ROIC: -24.75%
- Dividend Yield: N/A
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Vir Biotechnology, Inc. Investment Frameworks
Invetso analyzes Vir Biotechnology, Inc. (VIR) across the following frameworks:
- Vir Biotechnology, Inc. 10Y Growth Potential
- Vir Biotechnology, Inc. Scenario Analysis
- Vir Biotechnology, Inc. Risks & Opportunities
- Vir Biotechnology, Inc. Economic Moat
- Vir Biotechnology, Inc. Business Model
- Vir Biotechnology, Inc. Management
- Vir Biotechnology, Inc. SWOT Analysis
- Vir Biotechnology, Inc. Porter's 5 Forces
- Vir Biotechnology, Inc. PESTLE Analysis
- Vir Biotechnology, Inc. ESG Analysis